Details of the Drug Combination

General Information of Drug Combination (ID: DC3WEM1)

• Drug Combination Name: LY03004 + Cefmenoxime
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  LY03004 (DME5TUR): N.A.
  Cefmenoxime (DMPLY7B): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 5.3
  Bliss Independence Score: 5.3
  Loewe Additivity Score: 20.31
  LHighest Single Agent (HSA) Score: 20.32

Molecular Interaction Atlas of This Drug Combination

Indication(s) of LY03004

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Phase 3	[2]

Indication(s) of Cefmenoxime

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[3]

Cefmenoxime Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Bacterial Penicillin binding protein 3 (Bact mrcA)	TT85JMW	FTSI_ECOLI	Binder	[4]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [4] In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Antimicrob Agents Chemother. 1988 May;32(5):693-701.